



42 year old male who complains of asthenia, polydip-
sia and polyuria. He refers only heat intolerance. No fever, 
dysthermia or any other relevant data. Several recent tests 
carried out by his general practitioner (GP) show persistent 
hypercalcemia. He is admitted to the Rio Hortega University 
Hospital (Valladolid) to be studied.
Physical examination only shows discrete data referring 
skin and mucus dehydration.
The blood test run after the admission shows biochemi-
cal alterations (normal range in brackets): serum creatinine 
of 3.2 mg/dL (0.9-1.3), calcium of 13.9 mg/dL (8.6-10), urea 
of 75.8 mg/dL (12.8-42.8). The urine analysis presents urea 
levels of 1448 mg/dL. On the 24-hour urine test hypercalci-
uria is detected. Thyroid hormones' levels are normal and 
parathormone intact molecule is practically undetectable 
(<5 pg/mL). Haemoglobin is 11.3 d/dL (13.2-16.8). Tumour 
markers are normal.
the etiopathogenical relationship between 
sarcoidosis and primary hyperparathyroidism 
is not yet fully defined. this coexistence 
remains rare in medical literature despite their 
relatively high prevalence. therefore, this 
potential association should be considered in the 
differential diagnosis of a patient with sarcoidosis 
presenting symptoms of hyperparathyroidism.
in this paper we describe the case of a patient 
diagnosed with sarcoidosis who presented an initial 
episode of symptomatic hypercalcemia successfully 
treated with corticoids. after remaining asymptomatic 
for years, hypercalcemia reappears in several tests. 
the complete study on calcium metabolism leads the 
diagnosis toward primary hyperparathyroidism.
this case is relevant as it emphasizes the need to avoid 
attributing to hypercalcemia a reaction proper to 
sarcoidosis. thus, it is intended to highlight the need 
to approach differential diagnosis of hypercalcemia 
instead of administering a treatment with corticoids.
sarcoidosis, hyperparathyroidism, hypercalcemia.
Introduction
Sarcoidosis is an inflammatory disease of unknown etiol-
ogy. It causes non-caseating epithelioid granulomas, accu-
mulation of T lymphocytes and macrophages, frequent lung 
disease, hilar lymph nodes and skin, eye and renal manifes-
tations (4).
It has a worldwide distribution of unknown actual inci-
dence, since it usually presents few symptoms in incidental 
scans. The estimated prevalence is 40 cases / 100,000 popu-
lation in developed countries, being higher in young women.
The clinical course is variable and may resolve spontane-
ously. Manifestations may include increased absorption of 
calcium, as occurs in the present case, where symptomatic 
hypercalcemia is normalized after treatment with corticoids 
(3). Years later hypercalcemia is detected again, suspecting 
reactivation of the disease. A complete metabolic study re-
veals concomitant primary hyperparathyroidism, leading to 
radically changing the treatment.
The interest of this case lies in showing the importance of 
avoiding the tendency to initially diagnose hypercalcemia, 
approaching a differential diagnosis instead.
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In a subsequent check, months later, calcaemia and se-
rum ionic calcium remain elevated, with iPTH still very high. 
The treatment of choice is parathyroidectomy, extracting the 
parathyroid gland that contains the adenoma.
Discussion
In this patient, the reactivation of sarcoidosis would ex-
plain hypercalcemia, but not the increased PTH secretion, 
being suppression of PTH the normal physiological response. 
Thus, further investigation is considered in order to provide 
an alternative diagnosis to the persistent hypercalcemia.
Hypercalcemia is a frequent clinical finding, with primary 
hyperparathyroidism and malignancy as the most frequent 
etiologies. In malignancy, calcium levels are superior and 
clearly symptomatic. On the contrary, primary hyperpar-
athyroidism is usually diagnosed in healthy ambulatory pa-
tients, with mild or borderline hypercalcemia.
After detecting the hypercalcemia and carrying out a com-
plete anamnesis one should determine serum value for PTHi.
In the differential diagnosis, it should be taken into ac-
count that high levels of PTHi are usually due to primary 
hyperparathyroidism. In contrast, familial hypocalciuric hy-
percalcemia shows no significance increase of PTHi levels.
Granulomatous diseases, such as sarcoidosis, can show 
hypercalcemia and hypercalciuria. Calcium absorption is 
increased due to production of 1, 25-(OH) VitamineD3 and 
ACE. This translates into a serum increase of their levels. 
Parathyroid hormone (PTHi) would be diminished due to 
negative feedback (given elevated levels of 1, 25-(OH) 2D3) on 
parathyroid cells). This is synergic with the inhibitory effect 
that calcium synthesis has on these cells surface receptors 
(3, 6).
In further explorations, hilar and mediastinal adenopa-
thies are visible using X-ray and are confirmed by CT scan.
The fibrobronchoscopy shows a lymphoid cellularity of 
46%, 97% of which are CD3, 78% CD4 and 15% CD8, with 
CD4/CD8 of 5.2.
Transbronchial biopsy reveals non-caseating granulo-
mas. 
The abdominal echography demonstrates splenomegaly 
(maximum diameter of 14 cm) and nodular hypoecogenic 
diffuse echogenicity, consistent with secondary infiltration. 
Enhanced cortical echogenicity in both kidneys, consistent 
with nephropathy, is observed.
According to these results, the patient is diagnosed of 
state-II, active sarcoidosis, with hypercalcemia and second-
ary renal failure. Treatment with physiological saline, furo-
semide and corticoids is applied.
During the stay at the hospital, the patient shows clinical 
and analytical improvement, presenting the following levels 
before discharge: calcaemia 10.4 mg/dL, urea 60 mg/dL, cre-
atinine 1.8 mg/dL and PTH 20.7 pg/mL (12-72).
The follow-up is carried on an out-patient basis. He keeps 
a treatment based on prednisone (70 mg a day) with a de-
scending pattern for 3 months, omeprazole and enalapril (20 
mg a day).
For years, the patient evolves well, without progression in 
his illness on neither radiology checks (X-ray and CT scan) 
nor functional tests (spirometry, CO diffusing capacity). 
Calcaemia levels stay at a normal range.
After 7 years asymptomatic, hypercalcaemia is found dur-
ing a medical check, without accompanying symptoms.
The blood test shows high levels of calcaemia (10.18 mg/
dL), ionic calcium (5.33 mg/dL) and calcium/creatinine in-
dex in 24-hour urine (249.8 mg/g), creatinine (12.244); it’s 
preeminent the lack of suppression of parathyroid hormone 
(iPTH 128 pg/mL) (12-72); we find relatively normal levels of 
25-OH-Vitamin D3: 26 mcg/L (30-80) and normal ones of se-
rum angiotensin-converting enzyme.
Because of this, the diagnosis of primary hyperparathy-
roidism is considered.
A cervical and mediastinal study with 99mTc-MIBI and 
SPECT/CT is performed, finding a small round area, with 
mildly increased uptake, posterior to the inferior pole of the 
right thyroid lobe, giving the impression of a parathyroid 
adenoma. The study is completed with neck MRI (Magnetic 
Resonance Imaging) without contrast, that discloses an in-
crease in the size of the right inferior parathyroid gland, as 
well as cervical and mediastinal adenopathies.
▲ Figure 2. Scintigraphy with prolonged radiopharmaceuticals 
retention by right inferior parathyroid gland adenoma.
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▲ Figure 3. Differential diagnosis of hypercalcemia (8).
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Primary hyperparathyroidism shows hypercalcemia and 
increased PTHi serum levels. It can also be combined with 
hypercalciuria, hypophospatemia, increased 1, 25-(OH) 
vitamin D3, hypercloremia with metabolic acidosis and in-
creased bone turnover markers (alkaline phosphatase) and 
tubular calcium reabsorption. It also shows osteitis fibrosa 
by subperiostic reabsorption.
If primary hyperparathyroidism and clinically active sar-
coidosis coexist, ACE levels will be increased, with dimin-
ished PTH and phosphate levels when compared to inactive 
sarcoidosis.
Corticoids, alone or associated with other immunosu-
pressants, are the base of the treatment for sarcoidosis. 
Hypercalcemia in these patients should not be attributed to 
a reactivation of sarcoidosis, especially when there is no re-
sponse to treatment, as in the case presented.
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Primary hyperparathyroidism (PHPT) is caused by an 
augmented secretion of PTH on the parathyroid glands that 
manifests as hypercalcemia. It shows occasionally produced 
by an often solitary adenoma, localized in the lower glands, 
as is the case. 
Diagnosis is mainly biochemical: rise of total calcium and 
ionic serum levels with increased PTH levels. Imaging tech-
niques (CAT, MR and 99mTc-MIBI gammagraphy) are only 
used to locate the abnormal gland prior to the intervention. 
Parathyroidectomy is the basic treatment, after which nor-
mal calcium levels and analytical parameters are restored. 
Coexistence between sarcoidosis and primary hyperpar-
athyroidism are a rare clinical entity, with least than 100 
cases published since 1958, when first described (1, 3, 5). 
Even so, only individual or small series of cases with both 
diseases have been described. Hence, a definite relationship 
between both diseases has not been established, since both 
modify calcium metabolism through different mechanisms. 
However, it seems unlikely that this association is casual. 
Some authors consider both diseases have incidence high 
enough for concomitant emergence to occur. Other authors 
point out that sarcoidosis causes hypercalcemia, hypercalci-
uria and alterations of vitamin D dependent on calcium me-
tabolism. This would induce hyperplasia of the parathyroid 
glands, favoring the subsequent development of adenoma 
(4). There have been publications of cases in which sarcoido-
sis is diagnosed after the primary hyperparathyroidism (2, 3), 
sometimes without hypercalcemia at the time of diagnosis.
Conclusions
The association between primary hyperparathyroidism 
and sarcoidosis has relevant theoretical interest, since no 
etiopathogenical relationship has been established. 
Moreover, hypercalcemia can show more than one etiol-
ogy and sarcoidosis is one of the diseases that hinder the 
differential diagnosis of primary hyperparathyroidism. 
Diagnosis of both entities could be considered when 
evaluating hyperparathyroidism in the context of a patient 
suffering from sarcoidosis with hypercalcemia, changing the 
upcoming diagnosis and treatment radically (1, 2, 5).
When distinguishing both clinical entities one should 
bear in mind several aspects.
Sarcoidosis-based hypercalcemia shows fluctuant levels, 
diminished PTHi, normal or lower borderline  phosphate 
levels, increased 1,25-(OH)2D3, increased serum immuno-
globulins and increased red cell sedimentation serum ratio. 
When active, it shows even lower PTH and phosphatemia 
levels with increased ACE levels (1, 2, 3, 7).
